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The immune system interacts with developing cancer in ways that can protect the host against
hyperproliferation but that may also contribute to malignancy. Understanding the mechanisms
behind the protective and harmful effects of the innate and adaptive immune systems in their
exchanges with tumor cells will help to unravel how to harness our natural defenses with targeted
therapeutics. This issue’s Select delves into cancer immunoediting, T cell therapy, and how the
goodies can become the baddies during tumor growth.Expression of engineered TSAs (mea-
sured by luciferase activity) is lost during
sarcoma development in immunocom-
petent mice (left), whereas TSA expres-
sion is retained in the sarcomas if
T cells are depleted during tumor devel-
opment (right). Figure courtesy of
M. DuPage and T. Jacks.Editing Antigens
The rapid rejection of tumors generated in immunodeficient mice and then trans-
planted into a wild-type background suggests that immunogenic tumors are normally
quashed by healthy hosts. Only a few cells are predicted to escape immune surveil-
lance to grow and develop into full-blown tumors, either invisible to or actively sup-
pressing the immune response. Tyler Jacks and colleagues provide a striking
example of this process of cancer immunoediting in vivo, showing that tumor-specific
antigens (TSAs) are recognized by T lymphocytes, stimulating an immune response to
attack the tumor. TSA-expressing sarcomas induced in a K-Ras- and p53-deficient
background progress much more rapidly when Rag2 is also knocked out, a gene
that is essential for the generation of all lymphocytes. By linking expression of an en-
gineered TSA to luciferase, DuPage et al. (2012) show that sarcomas that manage to
develop in immune-competent mice downregulate their TSA (and thus luciferase)
expression, in contrast to Rag2 knockout mice, which express brightly fluorescing
tumors. This adds weight to the hypothesis that only those cells that can ‘‘hide’’ their
tumorigenic status from cells of the immune system can successfully grow in an
otherwise healthy organism. Preliminary results indicate that this TSA downregulation
could be due to epigenetic silencing through DNA methylation. Interestingly, geneti-
cally engineered sarcomas that do not express potent TSAs grown in Rag2 knockout
animals failed to engage the immune system when transplanted into wild-type mice,
showing that tumor immunogenicity is not a universal characteristic of cancer devel-
opment. Nonetheless, this study reveals the importance of TSAs in eliciting immune
responses against a developing tumor, spurring on efforts to identify such antigensand then engineer a patient’s T cells to respond to the TSAs expressed.
DuPage, M., et al. (2012). Nature 482, 405–409.Cancer immunoediting sculpts tumors by
causing downregulation of tumor-specific anti-
gens. Cartoon by K. Mahan.Finding a Different Type of T with Exome
Sequencing
A group led by Robert Schreiber and ElaineMardis uses cancer exome analysis
to analyze the contribution of T cells to cancer immunoediting. In this study,
Matsushita et al. (2012) sequence carcinogen-induced sarcomas that model
human cancers caused by smoking. Corroborating earlier studies as well as
work published simultaneously by DuPage et al. (2012), the authors show
that unedited sarcomas from Rag2 knockout mice are highly immunogenic
when transplanted into a wild-type mouse, whereas ‘‘escape’’ tumors from
awild-type background continue to grow strongly when transplanted to another
naı¨ve mouse. The authors predicted that mutant epitopes displayed in MHC
class I proteins on the surface of the tumor cells could be the trigger for T cell
responses to the unedited tumors in wild-type mice. In silico epitope prediction
analyses coupled with assays of cytotoxic T lymphocyte (CTL) activity reveal
that a missense mutation in the spectrin-b2 gene is a major rejection antigen
for cancer immunoediting in the sarcoma that was analyzed. Matsushita et al.
(2012) also show that, when mice are seeded with tumor cells expressing the
mutant spectrin-b2 gene, escape tumors that grew out in a wild-type back-
ground had lost expression of the mutant gene, and sequencing of the tumors
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seeded in a Rag2 knockout mouse grew vigorously and continued to express the mutant spectrin protein. This supports the
theory that T cell editing can select for cells that lose expression of major rejection antigens. This study highlights the power of
genomic sequencing to predict mutations that contribute to cancer immunogenicity. In the advent of whole-genome analyses
of single tumors and subpopulations of cells within a tumor, it is an exciting development that may inform personalized immu-
notherapies to treat the specific antigens that are present on individual tumors.
Matsushita, H., et al. (2012). Nature 482, 400–404.(Left)Thepreinfusioncontrast-enhancedCTscan
shows multiple enlarged 1–3 cm axillary lymph
nodes (example highlighted by arrows). (Right)
Scan at day 104 shows resolution of enlarged
lymph nodes, consistent with a complete
response. Image courtesy of D.L. Porter.Chimeric T Cells on a Seek and DestroyMission
As hinted at by the two studies described above, a tantalizing goal is to identify
tumor-specific antigens on cancer cells that, either through immunoediting or
other mechanisms, the immune system does not recognize and to then ‘‘spike’’
T cells to regain their tumor-fighting capabilities through gene transfer. Using
apatient’s ownTcells alsonegates the riskof graft-versus-host disease.Amajor
barrier to this type of approach, however, has been the difficulty in stimulating
clonal expansion of the engineered T cells after reintroduction into the patient,
with a consequent lack of clinical activity. Porter et al. (2011) have successfully
overcome this impedimentwith aclevermodificationof the intracellular domains
of a chimeric antigen receptor to include a combination of costimulatory
signaling domains. The antibody fragment conjugated to this base to act as
the antigen receptor is specific to CD19, which is abundantly expressed on Bcells in chronic lymphocytic leukemia (CLL). Lentiviral transfection of this chimeric construct into a refractory CLL patient’s
own T cells followed by reinfusion achieved complete remission of the cancer. Within a month of treatment, no traces of
CLL were visible in the bone marrow; 10 months later (at the point of publication of the report), the patient was still cancer
free, albeit with some toxicities associated with treatment. Remarkably, the engineered T cells had not only proliferated in
the blood, but a ‘‘memory’’-type response emerged,meaning that high levels of chimeric T cells persisted severalmonths after
treatment, presumably contributing to the continued suppression of the leukemia, but also to the concurrent B cell depletion
and hypogammaglobulinemia. If this technique is extended to target other cancers, a key issue will be to find antigens that are
truly tumor specific, as the persistence of these memory-type T cells could pose a threat to the remaining healthy tissue.
Porter, D.L., et al. (2011). NEJM 365, 725–733.Differential tumor growth in mice that
received irrelevant antibodies (top) vs.
depleting anti-CD8 (bottom). Figure
courtesy of M. Rutkowski, U. Scarlett,
and J. Conejo-Garcia.Dendritic Cells Switch Sides in the Fight
Cancer immunoediting is thought to generate tumors that are no longer immunogenic
to T cells. A recent study from Scarlett et al. (2012) provides evidence for the
additional contribution of dendritic cells in shaping the T cell response to a developing
tumor. Using a mouse model of ovarian cancer expressing only spontaneous tumor
antigens, the authors first verified that T cells were required for the control of the
tumor in the equilibrium phase: depleting CD8+ T cells rapidly increased the onset
of tumor escape and expansion. Then, advanced-stage tumor cell lysates were
used to stimulate responses from CD8+ T cells that had been isolated from either
early stage or late-stage cancers. Early stage tumor T cells were strongly stimulated
to produce interferon-g (IFNg), showing that the late-stage tumors (used in the
lysates) were still immunogenic. So why are the late-stage T cells not responsive to
tumor antigens? The authors show that the makeup of the immune infiltrate
surrounding a tumor changes dramatically at the transition point between tumor equi-
librium and expansion. Interestingly, it is the dendritic cells that present antigen to the
T cells that undergo the most significant phenotypic change between the two phases
of tumor development. In the presence of late-stage dendritic cells, T cells that were
shown to respond well to challenge with tumor cell lysate were now unable to mount an IFNg response. Conversely, early
stage dendritic cells stimulated the late-stage T cells into activity. The authors show that cytokines secreted by the tumor
remodel the stimulatory or suppressive nature of the dendritic cells. These intriguing results point to the importance of the
two-way interaction between the tumor and the immune system in shaping whether the tumor or the T cells have the upper
hand, via co-option of dendritic cells over to the other side of the battle. Thus, it is clearly vital to assess the tumor microen-
vironment when designing strategies to target tumor-specific antigens: controlling tumor-induced immunosuppression may
also be necessary (or even sufficient) for the implementation of effective anticancer immunotherapies.
Scarlett, U.K., et al. (2012). J. Exp. Med. Published online February 20, 2012. 10.1084/jem.20111413.
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